SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-18-135253
Filing Date
2018-04-26
Accepted
2018-04-26 17:31:54
Documents
10
Period of Report
2018-06-22

Document Format Files

Seq Description Document Type Size
1 PRE 14A d570336dpre14a.htm PRE 14A 165197
2 GRAPHIC g570336g04r88.jpg GRAPHIC 8526
3 GRAPHIC g570336g08i61.jpg GRAPHIC 28371
4 GRAPHIC g570336g25j46.jpg GRAPHIC 34741
5 GRAPHIC g570336g33q91.jpg GRAPHIC 41162
6 GRAPHIC g570336g40u60.jpg GRAPHIC 33097
7 GRAPHIC g570336g40w38.jpg GRAPHIC 56328
8 GRAPHIC g570336g50h64.jpg GRAPHIC 33703
9 GRAPHIC g570336g62y65.jpg GRAPHIC 22094
10 GRAPHIC g570336g96s45.jpg GRAPHIC 27629
  Complete submission text file 0001193125-18-135253.txt   549903
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 0630
Type: PRE 14A | Act: 34 | File No.: 000-51122 | Film No.: 18779910
SIC: 3826 Laboratory Analytical Instruments
Assistant Director 10